Great Point Partners’s Amicus Therapeutics FOLD Stock Holding History

Great Point Partners’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,495,500	Closed	-$14.8M	–	33
2024 Q2	$14.8M	Hold	1,495,500	–	–	2.84%	16
2024 Q1	$17.6M	Buy	1,495,500 +215,000	+17%	+$2.75M	2.75%	18
2023 Q4	$18.2M	Buy	1,280,500 +423,500	+49%	+$4.81M	3.1%	15
2023 Q3	$10.4M	Buy	857,000 +155,608	+22%	+$2.01M	1.9%	23
2023 Q2	$8.81M	Buy	701,392 +321,392	+85%	+$3.81M	1.72%	22
2023 Q1	$4.21M	Buy	+380,000	New	+$4.68M	0.83%	31
2021 Q4	–	Sell	-249,000	Closed	-$2.38M	–	41
2021 Q3	$2.38M	Sell	249,000 -1,351,000	-84%	-$13.8M	0.55%	34
2021 Q2	$15.4M	Buy	+1,600,000	New	+$15.6M	3.24%	12

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Great Point Partners's FOLD Position: Q3 2024 in Review

Great Point Partners sold out of Amicus Therapeutics (FOLD) in Q3 2024, closing a stake of 1,495,500 shares — an estimated $14.8M sold.

Great Point Partners first reported a position in FOLD in Q2 2021 and held it in 8 quarters. The position peaked at $18.2M in Q4 2023. 293 funds tracked by Wall St. Rank hold FOLD as of Q3 2024.

Great Point Partners reported no remaining Amicus Therapeutics position as of Q3 2024 after selling out during the quarter.
Great Point Partners sold 1,495,500 Amicus Therapeutics shares in Q3 2024, an estimated $14.8M.
Great Point Partners first reported a position in Amicus Therapeutics in Q2 2021 and held it in 8 quarters.
Great Point Partners's Amicus Therapeutics position peaked at $18.2M in Q4 2023.
293 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2024.

Based on Great Point Partners's 13F filing for Q3 2024, filed 13 Nov 2024.